Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Berking

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaB Schilling, W Sondermann, F Zhao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2015
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsM Hecht, L Zimmer, C Loquai, et al.
The British Journal of Dermatology|February 13, 2018
A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapyC A Morton, R Dominicus, P Radny, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2019
Sequence-dependent cross-resistance of combined radiotherapy plus BRAF<sup>V600E</sup> inhibition in melanomaB Shannan, J Matschke, H Chauvistré, et al.
The British Journal of Dermatology|September 14, 2011
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placeboT Dirschka, P Radny, R Dominicus, et al.
The British Journal of Dermatology|December 21, 2012
Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosisT Dirschka, P Radny, R Dominicus, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaB Schilling, W Sondermann, F Zhao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2015
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsM Hecht, L Zimmer, C Loquai, et al.
The British Journal of Dermatology|February 13, 2018
A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapyC A Morton, R Dominicus, P Radny, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2019
Sequence-dependent cross-resistance of combined radiotherapy plus BRAF<sup>V600E</sup> inhibition in melanomaB Shannan, J Matschke, H Chauvistré, et al.
The British Journal of Dermatology|September 14, 2011
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placeboT Dirschka, P Radny, R Dominicus, et al.
The British Journal of Dermatology|December 21, 2012
Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosisT Dirschka, P Radny, R Dominicus, et al.
Pageof 11